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Background & Aims: Endoscopic submucosal dissection (ESD) is a widely accepted treatment 
option for superficial gastric neoplasia in Asia, but there are few data on outcomes of gastric 
ESD from North America. We aimed to evaluate the safety and efficacy of gastric ESD in North 
America. 
Methods: We analyzed data from 347 patients who underwent gastric ESD at 25 centers, from 
2010 through 2019. We collected data on patient demographics, lesion characteristics, procedure 
details and related adverse events, treatment outcomes, local recurrence, and vital status at the 
last follow up. For the 277 patients with available follow-up data, the median interval between 
initial ESD and last clinical or endoscopic evaluation was 364 days. The primary endpoint was 
the rate of en bloc and R0 resection. Secondary outcomes included curative resection, rates of 
adverse events and recurrence, and gastric cancer-related death.      
Results: Ninety patients (26%) had low-grade adenomas or dysplasia, 82 patients (24%) had 
high-grade dysplasia, 139 patients (40%) had early gastric cancer, and 36 patients (10%) had 
neuroendocrine tumors. Proportions of en bloc and R0 resection for all lesions were 92%/82%, 
for early gastric cancers were 94%/75%, for adenomas and low-grade dysplasia were 93%/ 92%, 
for high-grade dysplasia were 89%/ 87%, and for neuroendocrine tumors were 92%/75%. 
Intraprocedural perforation occurred in 6.6% of patients; 82% of these were treated successfully 
with endoscopic therapy. Delayed bleeding occurred in 2.6% of patients. No delayed perforation 
or procedure-related deaths were observed. There were local recurrences in 3.9% of cases; all 
occurred after non-curative ESD resection. Metachronous lesions were identified in 14 patients 
(6.9%). One of 277 patients with clinical follow up died of metachronous gastric cancer that 




Conclusions: ESD is a highly effective treatment for superficial gastric neoplasia and should be 
considered as a viable option for patients in North America. The risk of local recurrence is low 
and occurs exclusively after non-curative resection. Careful endoscopic surveillance is necessary 
to identify and treat metachronous lesions.  
 
















BACKGROUND:   
Endoscopic resection is a minimally invasive technique for treatment of superficial 
gastric neoplasia with a negligible risk of lymph node metastasis and appears to be a safe 
alternative to radical surgery. Endoscopic mucosal resection (EMR) is a common endoscopic 
resection technique involving submucosal injection and/or suction and subsequent snare 
resection of the lesions1. However, EMR often results in piecemeal resection and is associated 
with high rates of local recurrence2, 3. Endoscopic submucosal dissection (ESD) was developed 
to overcome limitations of EMR. ESD allows en bloc resection of a superficial neoplastic lesion 
regardless of size, thus minimizing risk of local recurrence, and facilitates precise histological 
assessment of the resected specimen, and improves of curative resection2, 4. 
Numerous Asian studies, comparing ESD to surgery for EGCs fulfilling resection 
criteria, showed ESD has comparable outcomes in terms of overall and disease-specific survival. 
It is associated with a lower rate of adverse events, shorter hospital stay, lower cost, and better 
quality of life5-7. Thus, ESD is considered a safe and effective alternative to surgical resection 
and has become a treatment of choice for EGC and premalignant gastric lesions in Asia8, 9. 
In western countries, ESD has gained acceptance slowly, likely because of technical 
difficulty, time-consuming nature, steep learning curve and the lower incidence of gastric 
neoplasia. To date, outcomes data on gastric ESD in Western settings have been limited to small, 
single-center studies, with a lack of data from North America10-16. The 2019 American 
Gastroenterological Association recommends that, ESD should be considered as first-line 
therapy for visible, endoscopically resectable, superficial gastric neoplasia17. However, outcomes 
data for gastric ESD from US centers have not been published.   
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In the current study, we present a large multicenter analysis of safety, and clinical 
outcomes of ESD in North American population with superficial gastric neoplasia. 
 
METHODS: 
This was a retrospective analysis of consecutive patients with superficial gastric 
neoplasia who underwent ESD at 25 tertiary-care centers (22 in the USA and 3 in Canada). This 
study was approved by the institutional review board for human research at each institution.  
Inclusion criteria were cases with gastric dysplasia (LGD or HGD), EGC and NET. We 
excluded patients with Barrett’s adenocarcinoma, metastatic disease, and those who received 
prior chemotherapy or radiotherapy for gastric cancer. 
  Relevant clinical data were extracted including patient demographics, lesion 
characteristics, procedural details, procedure-related adverse events and treatment outcomes, 
presence of local recurrence, metastatic disease, and vital status at the last follow-up, when 
available. Well and moderately differentiated cancers were considered differentiated-type 
lesions, while poorly differentiated adenocarcinoma and signet-ring cell carcinoma were 
considered undifferentiated-type lesions. HGD is characterized by epithelium with both 
cytological and architectural changes. Carcinoma is diagnosed when the tumor invades into the 
lamina propria (intramucosal carcinoma) or through the muscularis mucosae.   
 
ESD procedures (Figure 1). 
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A transparent distal cap was attached at the distal end of the endoscope. Carbon dioxide 
insufflation was used for all procedures. Mucosal marking was carried out circumferentially 
around 5-10 mm outside the lesion margins using argon plasma coagulation or an ESD knife. A 
submucosal injection was performed using saline or other viscous solutions. Then a mucosal 
incision was made outside of the marking dots, followed by submucosal dissection using an 




Primary end points were the rates of en-bloc resection (defined as excision of the targeted 
lesion in a single specimen) and complete (R0) resection (defined as resection with lateral and 
deep margins free of gastric neoplasia on histopathology). Secondary outcomes included rates of: 
curative resection for EGC, adverse events, and recurrence and gastric cancer-related death.    
Curative resection was achieved when all of the following conditions were fulfilled 9, 18: 
an en bloc resection with negative horizontal and vertical margins and no lymphovascular 
invasion (LVI) and one of the following:  
(a). When the lesion is <2 cm in diameter, predominantly differentiated type, pT1a, and 
non-ulcerated, it is considered curative resection for standard criteria. 
(b). When a lesion is: (1) ≥2 cm in diameter, predominantly differentiated type, pT1a, and 
non-ulcerated; (2) <3 cm, predominantly differentiated type, pT1a, and ulcerated; (3) <2 cm, 
predominantly undifferentiated type, pT1a, and non-ulcerated; or (4) <3 cm, predominantly 
differentiated type, pT1b (SM1); it is considered curative resection for expanded indications.  
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Local recurrence was defined as the presence of endoscopic and/or histological evidence 
of neoplasia during follow-up endoscopy. Metachronous lesion was defined as a new gastric 
neoplasm in the area other than the site of the primary lesion diagnosed at least 12 months after 
the initial ESD. 
Severe intraprocedural bleeding was defined as clinical bleeding with a drop of 
hemoglobin >2 g/dL and/or with the need for blood transfusion. Delayed bleeding was defined as 
clinical evidence of bleeding by hematemesis or melena occurring any time from the time of 
ESD completion to 14 days after the procedure with a drop in hemoglobin >2 g/dL and/or 
requiring blood transfusion and/or endoscopic treatment.   
  
Statistical Analysis 
Frequencies and percentages were calculated for categorical variables and mean, standard 
deviation (SD), median and interquartile range (IQR) was calculated for continuous variables. 
Comparative analysis using Fisher’s exact test for categorical variables and the t tes  for 
continuous variables was performed. P values less than 0.05 were considered significant. 
 
RESULTS: 
Patients and Lesions Characteristics 
Of 354 patients who were referred for gastric ESD during the study period (2010-2019), 
ESD was technically feasible in 347 (98%). ESD was not technically feasible in seven cases (2 
due to deeply invasive cancer and 5 due to severe submucosal fibrosis from prior endoscopic 
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resection). In 347 gastric lesions that ESD was technically feasible, there were 90 (26%) 
adenomas/LGDs, 82 (24%) HGDs, 139 (40%) EGCs, and 36 (10%) NETs [Table 1]. Mean age 
was 69±12 years and 195 (56%) were males. Approximately half of the patients were Caucasian. 
 Most lesions were located in the antrum (167: 48%), followed by the gastric body (124: 
36%), fundus (33:10%) and gastric cardia (23: 6%). The mean lesion size was 26.8 mm (SD 16) 
[range 3-150]. Thirty lesions (9%) had previously undergone endoscopic therapy prior to gastric 
ESD. Of 36 gastric NET lesions, they were type I in 22, type III in 13 and type II in one. 
  Of 139 EGC lesions, ulcerative findings were observed in 33 (23.7%) lesions, and 59 
lesions (35.9%) had invaded to the depth of the submucosa or deeper. Most lesions (119; 85.6%) 
were differentiated type and LVI was detected in 29 (20.9%) of the lesions. Based on the Gastric 
Cancer Treatment Guidelines18, the clinical indications for ESD included absolute indications 
for 38 lesions (27.3%) and expanded indications for 88 lesions (63.3%) [(1) differentiated, non-
ulcerated, intramucosal, >2cm in 67; (2) differentiated, ulcerated, intramucosal, ≤3cm in 11 and 
(3) undifferentiated, non-ulcerated, intramucosal, ≤ 2cm in 10 cases]. ESD was performed for 13 
lesions (9.3%) outside of the established criteria. 
In the analysis of lesion characteristics and the presence of HGD and/or EGC in the 
resected specimen is showed in Supplement A (Supplementary Table 1). Comparison of tissue 
diagnosis from endoscopic biopsy and post-ESD histopathology is provided in Supplementary 
A (Supplement Table 2). 
Procedural Characteristics [Table 2]. 
Median procedure time was 90 min (IQR 60-138).  Overall, the Dual Knife (Olympus 
America, Center Valley, PA, USA) was the most commonly used electrosurgical ESD knife 
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(142; 41%). A combination of ESD knives was used in 29% of the cases. In 35% of cases 
(123/347), ESD was performed in an outpatient setting and 165 (47.6%) patients stayed 
overnight for clinical observation after ESD.   
 
Adverse events [Table 2]. 
Intraprocedural perforation occurred in 6.6% (n=23). Of these, 19 were treated 
successfully with endoscopic therapy and four (1.1%) required surgery. Severe intraprocedural 
bleeding occurred in 1.2% (n=4) and all were managed endoscopically. Delayed bleeding 
occurred in 9 cases (2.6%). Of these, five patients underwent repeat endoscopy with successful 
endoscopic hemostasis and the remaining patients were managed conservatively. No delayed 
perforation or procedure-related deaths were observed.   
 
Resection Outcomes 
En-bloc resection rates for all lesions, EGCs, adenomas/LGD, HGD, and NETs were 
92.2%, 93.5%, 93.3%, 89% and 91.7%, respectively. R0 resection rates for all lesions, EGCs, 
adenomas/LGD, HGD, and NET were 81.8%, 74.8%, 92.2%, 86.6% and 75%, respectively. 
[Table 3]  
In the adenomas/LGD group, all cases(n=7) with non-curative resection underwent 
endoscopic surveillance. Of 11 patients with HGD and non-curative resection, two underwent 
surgery due to piecemeal resection and nine patients elected not to have surgery. For 9 patients 
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with non-curative ESD for NETs, 4 patients underwent surgery and 5 patients did not undergo 
surgery either because they were unfit for surgery or declined additional treatment.     
 In the EGCs subgroup, after excluding 13 lesions outside clinical criteria for resection, 
curative resection according to Japanese criteria was achieved in 58.7% (74/126) of all EGC 
lesions, including 26 EGCs fulfilling the standard criteria and 48 EGCs fulfilling the expanded 
criteria. Reasons for non-curative ESD were presence of LVI in the resected specimen in 29; 
submucosal invasive cancer > 500 µm in 17; R1 resection in 35; and piecemeal resection in 5. Of 
52 cases with non-curative resection for EGCs, 22 patients underwent surgery, 2 patients await 
surgery and the remaining patients did not undergo surgery either because they were unfit for 
surgery or declined additional treatment. Of those 22 patients who underwent surgery, no 
residual cancer was identified at the resection site in 12 patients (55%).  Pathologic T staging of 
these 22 patients was T1a in 4 (18%), T1b in 13 (59%) and T2 in 5 (23%). Two resection 
specimens (2/22, 9%) showed micrometastases in the lymph nodes and 20 (91%) were classified 
as pN0.      
 
Follow-up and recurrences 
A total of 203 patients who did not undergo surgery underwent follow-up endoscopy. The 
median total endoscopic follow-up was 239 days (IQR: 114-239) after the index gastric ESD. 
Local recurrences: 
Eight out of the 203 patients (3.9%) experienced a residual lesion or local recurrence, and 
all occurred after non-curative ESD resection. One patient with local recurrence after piecemeal 
resection of gastric adenoma was successfully treated by EMR. Two patients with residual 
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lesions after R1 resection of HGD underwent repeat endoscopic resection but it was 
unsuccessful. One of these two patients underwent surgery and the other patient declined 
surgery. One patient with local recurrence after non-R0 resection of a 2 cm intramucosal well-
differentiated adenocarcinoma underwent further ESD and complete resection was achieved. 
One patient with local recurrence after non-R0 resection of a 2 cm intramucosal well 
differentiated adenocarcinoma underwent surgery. One patient with local recurrence after non-
curative ESD for a 3 cm submucosally invasive poorly differentiated adenocarcinoma underwent 
surgery. One patient with a 3 cm submucosally invasive moderately differentiated 
adenocarcinoma was found to have LVI on the resected specimen and was subsequently found to 
have local recurrence but declined additional treatment. One patient with local recurrence after 
non-curative ESD for a 4 cm intramucosal moderately differentiated adenocarcinoma underwent 
additional EMR of the residual tumor during follow-up endoscopy, however complete resection 
was unsuccessful. 
In the EGC group, there were 5 (7.1%) local recurrences after ESD (0% (0/43) after 
curative resection vs 18.5% (5/27) after non-curative resection, p=0.007).     
Metachronous lesions: 
Of 203 patients, including those with non-curative ESD resections, 14 (6.9%) developed 
metachronous lesions during follow-up endoscopy. Seven lesions were treated with EMR, 4 with 
surgery and 2 patients were monitored without treatment. One patient who underwent curative 
ESD for a 24 mm LGD developed metachronous high-grade neuroendocrine carcinoma at 2.5 
years after the initial ESD.  
Gastric cancer mortality: 
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Clinical follow-up was available in 277 of 347 patients after ESD. The median interval 
between initial ESD and last clinical/endoscopic follow up was 364 days (IQR 130-682). One 




To date, outcomes data on gastric ESD in the Western settings have been limited to 
small, single-center studies, with a lack of data from North America. In this study, we report on 
347 superficial gastric lesions treated with ESD at 25 tertiary care centers in North America. To 
our knowledge, this is the largest series on gastric ESD published from Western centers. The 
resected 347 gastric lesions included 90 adenomas/LGDs, 82 HGDs, 139 EGCs, and 36 NETs. 
En-bloc resection was achieved in 92.2% and R0 resection was achieved in 81.8% of all lesions. 
Adverse events included a perforation rate of 6% and a postprocedural bleeding rate of 2.6%. 
Surgery was performed for ESD-related adverse events in 1.1% of cases. Altogether, ESD 
appears to be a highly effective treatment for superficial gastric lesions in a Western setting. 
 In the meta-analysis on resection outcomes of gastric ESD from Eastern countries 
involving 59,173 gastric lesions, en-bloc resection and R0 resection rates were 94% and 91%, 
respectively. The pooled rate for perforation was 2.6% and for bleeding was 4.2%19. Studies 
from Europe and South America reported en-bloc resection rates of 87-100%, R0 resection rates 
of 64-93%, perforation rates of 0-10% and bleeding rates of 1-8%12, 13, 15, 16, 20-22. The resection 
success rates of our study are slightly lower than those from Eastern studies and comparable to 
those of other Western studies. This may be explained by the lower incidence of gastric 
neoplasia in North America as compared to Asia, and the fact that ESD is not yet widely 
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available in the West because the procedure is technically demanding and entails a steep learning 
curve. Comparing to EMR, a meta-analysis of non-randomized studies showed that ESD offers 
considerable advantages regarding higher en-bloc resection rate (92% vs. 52%), histologically 
complete resection rate (82% vs. 42%), and lower local recurrence (1% vs. 6%), even for lesions 
smaller than 10 mm23. Given these results, the European guidelines recommend ESD as 
treatment of choice for most gastric superficial neoplastic lesions. EMR is an acceptable option 
for lesions smaller than 10-15mm with a very low probability of advanced histology (Paris 0-
IIa)2.  
Curative resection of EGC was defined according to the Japanese Gastric Cancer 
Association18. The meta-analysis of Eastern studies reported a curative resection rate of 80%19. 
In our study, curative resection rates of 59% in the EGC group appeared lower than that of other 
Western series. The lower rates of curative resection in this study may be explained by 
differences in the types of lesions included in the analysis. One Australian study22 reported an 
overall curative resection rate of 79%. However, that study combined HGD into the EGC group, 
while our study separated HGD from the adenocarcinoma category. In this study, we noted the 
rate of histologically complete resection in the HGD group was 86.6%. Thus, our curative 
resection rate would be higher if we combined HGD with T1a cancer. In addition, a significant 
proportion of the resected lesions in this study were lesions with LVI or submucosal invasive 
cancer > 500 µm, which could not be precisely determined prior to ESD.        
 Gastric adenoma and/or LGD is a precancerous lesion to gastric adenocarcinoma with an 
annual risk of progression to cancer of 0.77%24. Because lesions initially reported as gastric 
adenoma with LGD by endoscopic biopsy can be upgraded to invasive cancer in up to 25% of 
cases after total endoscopic resection, complete en-bloc resection is desirable25, 26. In this study, 
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we found that ESD is highly effective in achieving complete resection of gastric adenoma/LGD 
with en bloc and R0 resection rates of 93% and 92%, respectively. The risk of 
metachronous cancer after endoscopic resection of gastric adenoma/LGD is similar to that of 
EGC (14.4 cases per 1000 person-years)26. Thus, careful endoscopic surveillance to identify 
metachronous lesions after endoscopic resection should be considered for both gastric adenoma 
and EGC patients with the same level of intensity.   
  There are differences in the threshold for diagnosing HGD and early carcinoma in the 
West versus Japan. The lesions classified as HGD by Western pathologists are frequently 
diagnosed as adenocarcinoma in Japan. This is particularly important because a small fraction 
(6%) of lesions that would be labeled as HGD by most US pathologists on the basis of the WHO 
criteria show venous and/or LVI27. In this study, the HGD group was differentiated from EGC to 
further characterize ESD outcomes for this type of lesion. R0 resection for HGD was 86%, 
which was similar to that of the adenoma/LGD group (92%; p=0.32) but higher than the EGC 
group (74%, p=0.04).  
In this study, with a median endoscopic follow-up of 8 months, local recurrence was low 
at 3.9% and occurred after non-curative resection. In a study from Germany, curative treatment 
was achieved with ESD in 100 % of the standard criteria group and 89.7 % of the expanded 
criteria group after a median follow-up of 51 months and 56 months, respectively. No gastric 
cancer-related death was observed21. These excellent long-term results suggested effectiveness of 
ESD in the Western setting. 
 Few reports have evaluated the efficacy of ESD for gastric NET, and all were small 
single center studies from Asia8, 28, 29. Complete resection rate ranges from 94-100% with ESD. 
The overall metastatic risk is low in type 1 gastric NETs and moderate in type 2, and has been 
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directly correlated with tumor size. Management of low risk gastric NET is controversial. 2017 
ASGE guidelines suggested that EMR may be considered for types I and II gastric lesions ≤2 
cm. Lesions <1 cm may not require removal; however, surgical resection is often warranted for 
larger lesions30. According to European Neuroendocrine Tumor Society, for lesions <1 cm, 
surveillance or endoscopic resection could be considered, while resection should be performed 
for tumors ≥1 cm31. A retrospective study suggested that ESD, as compared to EMR, was 
associated with a higher complete resection rate (94% vs 83%)8. We found ESD is effective, 
with high rate of complete resection for gastric NETs in a Western setting, and should be 
considered if expertise is available.    
The main strength of this study is that it is the largest series of gastric ESD as therapy for 
EGCs and premalignant gastric lesions in a North American population that is derived from 
multiple tertiary centers, which increase the generalizability of these results. The study’s 
limitations include its retrospective design and lack of long-term follow-up data. Lastly, almost 
half of the patients in this study had severe systemic disease, which could indicate selection bias 
toward endoscopic resection rather than surgery, and may not allow for long-term follow-up for 
oncologic outcomes.  
In summary, this is the first multicenter study from North America on ESD in patients 
with EGCs and premalignant gastric lesions to demonstrate a high rate of complete resection 
with acceptable safety profiles. To our knowledge, this is the largest study on gastric ESD for 
superficial gastric neoplasia in the Western world. Based on these data, we recommend ESD 
should be considered as a potential treatment option for superficial gastric neoplasia. Additional 
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 Figure 1. Gastric endoscopic submucosal dissection (ESD) of an intramucosal cancer. (A-B) 
White light image demonstrates a depressed lesion (Paris 0-IIc) at prepyloric antrum; (C) After 
marking outside the lesion margins, mucosal circumferential incision was performed; (D) 
Submucosal dissection; (E) ESD mucosal defect; (F) Resected specimen. 
 
Table 1. Patient and tumor characteristics   
 N = 347 
Gender (male, n, %) 195 (56%) 
Age (years, mean, SD) 69 (±12) 
Race (n, %):  
     Caucasian  161 (46%) 
     Asian  79 (23%) 
     Hispanic 28 (8%) 
     African American 22 (6%) 
     Others 8 (2%) 
     Unknown 49 (15%) 
ASA class (n, %)  
     I [normal healthy patient] 17 (5%) 
     II [mild systemic disease]  164 (47%) 
     III [severe systemic disease] 153 (44%) 
     Unknown 13 (4%) 
Prior endoscopic treatment (n, %) 30 (9%) 
Histology of the lesion (n, %)  
     Early gastric cancer 139 (40%) 
          Well- or moderately differentiated grade  119 (34%) 
           Poorly differentiated or signet ring cell type 20 (6%) 
     Adenoma/ Low-grade dysplasia 90 (26%) 
     High-grade dysplasia 82 (24%) 
     Neuroendocrine tumor 36 (10%) 
Location of tumor (n, %)  
     Fundus 33 (10%) 
     Gastric body 124 (36%) 
     Antrum 167 (48%) 
     Cardia  23 (6%) 
Tumor size, mm (mean, SD, range) 26.8 (SD: 16) [range 3-150] 
      ≤ 20 162 (47%) 
      21 – 30  98 (28%) 
      > 30 87 (25%) 
Paris classification (n, %)  
     Ip 25 (7%) 
     Is  103 (30%) 
     IIa  86 (25%) 
     IIb 26 (7%) 
     IIc or IIa + IIc or IIc + IIa 85 (25%) 
     IIa+Is 8 (2%) 
     Unknown 14 (4%) 




Table 2. Procedure data and adverse events 
 N = 347 
Procedure 
Type of primary knife for ESD (n, %)   
      Dual knife 142 (41%) 
      IT-2 knife 105 (30%) 
      Hybrid knife 78 (22%) 
      Hook knife 5 (1%) 
      Flush knife 10 (3%) 
      Triangle tip knife 3 (1%) 
      Others 4 (1%) 
Combination of ESD knives (n, %) 176 (29%) 
Procedure time (minutes, median, IQR)  
[data available in 310 cases] 
90 (IQR: 60-138) 
Hospitalization following ESD (n, %)  
     Outpatient procedure with discharge home  123 (35%) 
     Overnight observation   165 (47.6%) 
     Hospitalization 2 days or longer 59 (17%) 
Adverse events 
Intraprocedural perforation (n, %) 23 (6.6%) 
     Successfully management with endoscopic closure 19   
     Need emergent surgery due to perforation 4  
     Severity of intraprocedural perforation  
            Mild 17 
            Moderate 2 
            Severe 4 
Severe intraprocedural bleeding (n, %) 4 (1.2%) 
     Severity of severe intraprocedural bleeding  
            Mild 4 
Delayed bleeding (n, %) 9 (2.6%) 
     Severity of delayed bleeding  
            Mild 3 
            Moderate 4 
            Severe 2 
Pulmonary embolism (n, %) 1 (0.3%) 
     Severity of pulmonary embolism  
            Severe 1 
Dyspnea (n, %) 1 (0.3%) 
     Severity of dyspnea  
            Moderate 4 




Table 3. Resection outcomes  
Outcomes, n 
(%)  
Total Early gastric 














84/90 (93.3%) 73/82 
(89.0%) 
33/36 (91.7%) 










28/334 (8.9%) 22/126 
(17.6%)** 





     
Residual/local 
recurrence 











1/203 (0.49%) 0/70 (0%) 1/59 (1.7%) 0/56 (0%) 0/17 (0%) 
Death       
     Gastric 1/277 (0.4%) 0/111 (0%) 1/75 (1.3%) 0/64 (0%) 0/27 (0%) 
cancer 
     Non-
gastric cancer  
9/277 (3.2%) 8/111 (7.2%) 1/75 (1.3%) 0/64 (0%) 0/27 (0%) 
*Curative resection according to Japanese criteria was 58.7% (74/126)  
# Of 139 EGCs, the T staging was T1a in 86, T1b in 48, T2 in 2 and undetermined due to piecemeal 
resection in 3.  





Need to Know 
 
Background: Endoscopic submucosal dissection (ESD) is a widely accepted treatment option for 
superficial gastric neoplasia in Asia, but there are few data on outcomes data on gastric ESD 
from North America. 
 
Findings: In an analysis of a large cohort of patients with superficial gastric neoplasia who 
underwent ESD at 25 centers across North America, the authors found the high rates of en bloc 
(92%) and R0 resection (82%), with acceptable safety profiles. The rate of local recurrence was 
low, and occurred only after non-curative resection.  
 
Implications for patient care: These findings support the use of ESD for as a treatment option for 
superficial gastric neoplasia in North American populations. 
 
 
